What's the rush? The dissemination and adoption of preliminary research results.
Steven
S
Woloshin
Lisa M
LM
Schwartz
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D003226:Congresses as Topic; D004059:Diffusion of Innovation; D019317:Evidence-Based Medicine; D005260:Female; D000077156:Gefitinib; D006801:Humans; D033181:Information Dissemination; D008175:Lung Neoplasms / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D010818:Practice Patterns, Physicians' / Q000592:standards*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077156:Gefitinib